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a  b  s  t  r  a  c  t
Objective: The goal of this study was to determine the prevalence of human papillomavirus
infection infection and cervical lesions and its associated factors among HIV infected
women attending an AIDS clinic in Amazonas state, Brazil.
Methods: Cross-sectional study. Women attending an AIDS clinic in the city of Manaus
between March and December 2011 for gynecological examination were invited to par-
ticipate. Enrolled patients answered a standardized interview including demographical,
behavioral, and clinical data. Additionally, patients underwent a gynecological evaluation
with collection of cervical samples for cytological analysis and high-risk human papillo-
mavirus infection hybrid capture. A blood sample was also obtained to determine CD4 and
viral  load levels.
Results: A total of 310 (82.9%) women participated in the study. High-risk human papillo-
mavirus infection was detected in 191 (61.6%) cases; 24 (13.5%) had low-grade squamous
intraepithelial lesion (SIL) and 4 (2.2%) high-grade SIL. No invasive cervical cancer was diag-
nosed. Median age was 32 (interquartile range (IQR): 27–38) years and median of education
was 8.5 (IQR 4–11) years of schooling and 56.1% had a monthly income up to US$180. In mul-
tivariate analysis, being less than 30 years old [OR = 1.7 (95% CI: 1.2–2.4, p = 0.005)], high-grade
SIL [OR = 6.5 (95% CI: 1.6–23.0, p = 0.009)], and CD4 counts <200 cells/mm3 [OR = 1.6 (95% CI:
1.2–2.0,  p < 0.001)] were associated with high risk human papillomavirus infection infection.
Conclusions: In the present study high-risk human papillomavirus infection was frequentand it was associated to h
inations in routine care an
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Introduction
Although screening for cervical cancer is recommended for
women in most countries, with varying age range and peri-
odicity of testing, the incidence of cervical cancer and its
related mortality is far greater in developing countries.1 Inva-
sive cervical cancer (ICC) is the second most common cancer
in women of childbearing age in Brazil2 and about 15.1% of
women in the general population are estimated to be infected
by cervical human papillomavirus infection (HPV) in 2012.2 An
estimated 15,590 new ICC cases will be diagnosed in Brazil in
2014 (15.33/100,000 women).3
Cervical cancer is the most incident in northern Brazil
(23.57/100,000). In the state of Amazonas the ICC is a concern
because it has the highest incidence rate estimated in Brazil
(630 cases; 35.13/100,000 women) in 2014. In the same year, the
capital city of Manaus had an estimated rate of three and a half
times greater than that expected for the country besides hav-
ing the highest incidence rate among Brazilian capitals (510
cases; 53.3/100,000 women).3
The spread of HIV/AIDS in northern Brazil and in the State
of Amazonas, in particular, is worrisome especially by the vul-
nerability of this geographical area, which is determined by
the ethnic-cultural diversity of their inhabitants.4,5 The pre-
carious living conditions of the population, and the lack of
access to basic needs and health care, given the magnitude of
the disease and current epidemiological trends, are important
issues in this population, especially regarding hospital beds
availability.6
In Brazil the total cumulative cases of AIDS from 1980
to June 2014 was 757,042 cases and 35.0% of this total were
women. The mortality rate for women was 4.3/100,000 inha-
bitants (2013), observing an increase of 3.9 deaths per 100,000
inhabitants in 2004 to 4.3 in 2013. In 2013, the incidence rate of
AIDS in the Amazon state was the second largest in the coun-
try (37.4/100,000 inhabitants), and the mortality rate for the
third largest (8.7/100,000 inhabitants). The capital city of Man-
aus had the third highest incidence rate of AIDS among all
Brazilian capital cities (59.7/100,000 inhabitant), with a mor-
tality rate of 12.5%.7
Women infected by HIV present signiﬁcantly higher rates
of squamous intraepithelial lesions (SIL) and are more  sus-
ceptible to invasive cervical carcinoma progression than
HIV-negative women.8–11 The prevalence of HPV infection
is usually greater in HIV-infected women12,13 and it might
be explained by the maintenance of high plasma14 and
genital15 viral load and persistent HPV infection10,15–17 as a
result of HIV infection, which increases the risk to develop
SIL.14–18
Wherever HIV-infected women have access and good cov-
erage to cervical cancer screening, they will have better
prognosis as a consequence to early diagnosis and treatment
of cervical lesions, avoiding progression to cancer. There are
not published data focusing on this problem in Amazonas and
these results of the present can be used to elaborate preven-
tion strategies for this population. The goal of this study was to
evaluate the prevalence of HPV infection and cervical lesions
in women infected by HIV attending an AIDS clinic in Manaus,
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Material  and  methods
This was a cross-sectional study conducted among HIV-
infected women who attended the AIDS clinic of a tertiary
referral hospital in the city of Manaus, Amazonas, Brazil,
between March and December 2011. The hospital was the
Tropical Medicine Foundation Dr. Heitor Vieira Dourado (FMT-
HVD) in the city of Manaus. The total of women infected by HIV
registered at FMT-HVD was 2062 cases. In the study period 419
patients, attending the clinic for routine gynecological exam-
ination, were invited to participate. In order to be included
in the study women had to have a conﬁrmed anti-HIV result,
be aged 18–49 years, and agreed to participate. The exclusion
criteria were pregnancy at the time of study, previous hysterec-
tomy, or history of cervical conization (Fig. 1).
Enrolled patients answered a face-to-face standardized
interview including demographic, behavioral and clinical data,
after signing the informed consent form. They also under-
went a gynecological evaluation and cervical samples were
collected for cytological analysis, which followed the rec-
ommendations of the Brazilian Ministry of Health.19 The
classiﬁcation used for cytological results was the Bethesda
System for epithelial cell abnormalities – atypical squamous
cells of undetermined signiﬁcance (ASC-US); Cannot exclude
HSIL (ASC-H); Low-grade squamous intraepithelial lesion
(LSIL); High-grade squamous intraepithelial lesion (HSIL).19
Colposcopic abnormalities were biopisied and submitted to
histological analyses. A blood sample was obtained to deter-
mine CD4 and viral load levels.
Samples for molecular biology tests were collected prior
to the collection for cytology. The test used for detecting HPV-
DNA was the (HC2) low (6, 11, 42, 43 e 44) and high risk (HPV 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 e 68) Hybrid Capture2V2®.
The samples were collected using brush-type “cytobrush,”
which are part of HC2 (DIGENE®) to microwell hybridization
signal ampliﬁcation by detecting chemiluminescence to qual-
itatively detect HPV. Hybrid capture was also performed for
Chlamydia trachomatis.
Samples were transported in room temperature conditions
right after specimen collection or in low temperatures (−2 to
8 ◦C) when there was a delay of up to two days after collection
before sending to the Laboratory of Molecular Biology of the
FMT-HVD in Manaus, Amazonas.
The primary outcome variable was HPV positivity for lower
and/or high-risk genotypes, deﬁned as any positive HC2. To
determine factors associated with the prevalence of high
risk HPV, predicting variables such as demographic, behav-
ioral, and clinical data were examined. Demographic variables
included were state of origin, age in years, years of schooling,
marital status, monthly income, and tobacco use. Behavioral
variables were age at ﬁrst sexual intercourse, regular condom
use, previous sexual violence, commercial sex work, practice
of anal sex, homosexual relationship, illicit drug use, and
injecting drug use. Clinical variables were genital bleeding,
cervical cytology results and Chlamydia trachomatis test results,
CD4 counts and viral load level at HPV diagnosis, as well as
infection status (categorized as HIV infection or AIDS).
Data were analyzed using the SPSS 17.0. A prelimi-
nary analysis was performed using exploratory techniques.
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Recruitment of HIV-infected women or with AIDS
of the SAE/FMT-DHVD
n=2.06 2 
Accessed eligible women 
n=419 
Inclusion criteria 
HIV-infected  women  or wi th AIDS  
Age 18 to 49 years 
They agreed to participate 
conducted  inter view and colle ction of ma teria l for 
laboratory tests 
Women  in cluded 
n=374 
Study populatio n 
n=31 0 
Exclusion criteria 
Diagnosis of pregnancy at the time  
n = 01 of study sampling 
n = 01 Previous hysterectomy 
n = 00 History of cervical conization  
n = 01 Age greater than 49 
n = 05 Duplication of participation  
Women did  not  perform  sample   
























cFig. 1 – Flow diagra
hi-square tests, Student’s t tests and analysis of variance
ere used. The odds ratio was used as a measure of associa-
ion, estimated with a 95% conﬁdence interval and those with
 < 0.05 were considered to be signiﬁcantly associated with the
utcome variable (high-risk HPV). Multivariate analysis was
erformed to determine variables independently associated
he outcome of interest, through the use of logistic regres-
ion models. All variables with a p ≤ 0.15 in univariate analyses
ere included in multivariate analysis.
This study was submitted to and approved by the inter-
al review board of the Amazonas FMT-HVD #327-09/2009.
ritten consent was given by the patients for their infor-
ation to be stored in the hospital database and used for
esearch.
esults
his study evaluated 419 women, 374 met  the eligibility crite-
ia. Eight cases were excluded because of pregnancy, previous
ysterectomy, age greater than 49 years old, and duplication of
articipation. After the interview, 56 women did not undergo
ample collection. A total of 310 (82.9%) women were included
n the study (Fig. 1). All women were on antiretroviral therapy
ART).
High-risk HPV was detected in 191 (61.6%) cases; 24 (13.5%)
ad LSIL and four (2.2%) HSIL. There were no cases of invasive
ervical cancer. study participants.
Median age was 32 (interquartile range (IQR): 27–38) years
and median of education was 8.5 (IQR 4–11) years of school-
ing. A total of 56.1% had a monthly income up to US$180.
Table 1 shows demographic data; age was the only variable
signiﬁcantly different between groups.
Behavioral features are described in Table 2: 9.7% were
tobacco users, 49 (15.8%) illicit drug abusers, 220 (71.0%) used
condoms regularly in last year, and 49 (15.8%) were commer-
cial sex workers. There was no difference between the two
groups.
The median of CD4 + T cell counts and of viral load was
338.5 (IQR = 211.5–513.3) cells/mm3 and 497.5 (IQR = 49–11,288)
copies/mm3 respectively. A total of 165 (53.2%) HIV infected
women were classiﬁed as patients with AIDS. The HPV
infected women were different from HPV uninfected group
regarding CD4 count less than 200 (28% vs. 10.2%, p < 0.001)
and HSIL (3.7% vs. 0.8%, p = 0.001). Clinical data are described
in Table 3.
In multivariate analysis, being less than 30 years old
[OR = 1.7 (95% CI: 1.2–2.4, p = 0.005)], HSIL [OR = 6.5 (95% CI:
1.6–23.0, p = 0.009)], and CD4 count <200 cells/mm3 [OR = 1.6
(95% CI: 1.2–2.0, p < 0.001)] were associated with high risk HPV
infection in the ﬁnal model.Discussion
This study found a high prevalence of high risk HPV in HIV
infected women in Manaus. These results underscore the
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Table 1 – Demographical characteristics of the 310
participants HIV women, attendees of the service of







Amazonas State 157 (82.2) 91 (76.5) 0.143
Other States in North 25 (13.1) 19 (16.0)
Other Regions 9 (4.7) 9 (7.5)
Age in years
18–29 80 (41.9) 28 (23.5) 0.002
30–39 81 (42.4) 60 (50.4)
≥40 30 (15.7) 31 (26.1)
Education in years
Up to 4 50  (26.2) 30 (25.2) 0.916
5–8 48 (25.1) 27 (22.7)
≥9 93 (48.7) 62 (52.1)
Marital status
Single 61 (31.9) 33 (27.7) 0.621
Married/living together 97 (50.8) 69 (58.0)
Separated/divorced 21 (11.0) 12 (10.1)
Widow 12 (6.3) 5 (4.2)
Monthly income
Up to one BMIa 116 (60.7) 58 (48.7) 0.194
1.1–3 BMI 60 (31.4) 46 (38.7)
More than 3 BMI 15 (7.9) 15 (12.6)
a One BMI = US$180 in 2011.
Table 2 – Behavior characteristics of the 310 participants
HIV women, attendees of the service of specialized care






Age at ﬁrst intercourse
≤15 years 95 (49.7) 51 (42.7) 0.233
>15 years 96 (50.3) 68 (57.3)
Regular condom use
Yes 135 (70.7) 85 (71.4) 0.777
No 56 (29.3) 34 (28.6)
Previous sexual violence
Yes 70 (36.6) 41 (34.5) 0.779
No 121 (63.4) 78 (65.5)
Sex workers
Yes 35 (18.3) 14 (11.8) 0.333
No 156 (81.7) 105 (88.2)
Practice of anal sex
Yes 59 (31.4) 37 (31.1) 0.836
No 131 (68.6) 82 (68.9)
Homosexual relationship ever
Yes 9 (4.7) 5 (4.2) 0.317
No 182 (95.3) 124 (95.8)
Illicit drug use
Yes 33 (17.3) 16 (13.4) 0.368
No 158 (82.7) 103 (86.6)
Injecting drug use
Yes 3 (1.6) 1 (0.8) 0.579
No 188 (98.4) 118 (99.2)
Table 3 – Clinical characteristics of the 310 participants
HIV women, attendees of the service of specialized care







Yes 20 (10.5) 11 (9.2) 0.735
No 171 (89.5) 108 (90.8)
Cervical cytology results
Normal 157 (82.2) 116 (97.5) <0.001
Low grade SILa 27 (14.1) 2 (1.7)
High grade SIL 7 (3.7) 1 (0.8)
Chlamydia trachomatis test
Positive 11 (5.8) 3 (2.5) 0.262
Negative 180 (94.2) 116 (97.5)
CD4 counts at HPV diagnosis
≤200 cells/mm3 54 (28.0) 12 (10.2) <0.001
201–349 cells/mm3 56 (29.1) 36 (30.5)
350–500 cells/mm3 48 (25.4) 20 (16.9)
>500 cells/mm3 33 (17.5) 51 (42.4)
Viral load (copies/ml)
≤1000 94 (49.2) 71 (59.7) 0.073
>1000 97 (50.8) 48 (40.3)
Infection status
HIV 89 (46.6) 56 (47.1) 0.725
AIDS 102 (53.4) 63 (52.9)a SIL, squamous intraepithelial lesions.
importance of routine gynecologic examinations and follow-
up in those who present with cervical lesions. These results
are in agreement with other Brazilian10,20–23 and international
studies12–14,24,25 that showed high prevalence of high risk HPV
among HIV infected women.
It is important to emphasize that it was found low preva-
lence of HSIL in this group and there was no invasive cervical
cancer. These ﬁndings could be explained by the high rate
of ART use and by the higher access of HIV infected women
to gynecological care in Brazil. As they go to the clinic to be
followed for the HIV infection they are also more  frequently
submitted to pap smear and can therefore be diagnosed ear-
lier.
HPV is considered one of the most important risk factors
for cervical cancer.26–28 In the present study high risk HPV was
associated to HSIL. HPV infection and SIL are common in HIV
infected women,12–14,29–31 who may be asymptomatic. As HIV
infected women may have faster progression, all women with
SIL must be tested for HIV, because it might be a signal of
immunosuppression.14,31 Factors related to HPV infection also
contribute to progression of the infection to cancer, such as
HPV genotype, viral variants, persistence of infection, and viral
load.15,32,33 The high-risk types are more  likely to cause persis-
tent lesions and be associated with precancerous lesions.25,34
Other associated factor with high risk HPV in this study
was lower CD4 lymphocyte cells counting (<200 cell/mm3).
Other studies suggested that the frequency of HPV persis-
tence varied inversely with CD4+ count, and found higher
HPV prevalence and incidence of oncogenic HPV types in
HIV infected patients, especially those with lower CD4+
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ounts.13,18,31 These data suggest that the level of CD4 is
mportant in the pathogenesis of HPV infection in HIV infected
atients.25,31
Cross-sectional studies can be carried out to investigate
ssociations between risk factors and the outcome of inter-
st. They are limited, however, by the fact that they are carried
ut at one time point and give no indication of the sequence
f events. For this reason, it is impossible to infer causality. Its
pplication is justiﬁed in this study for assessing the preva-
ence of and the associated factors for high risk HPV among
IV infected women. It is important to demonstrate the sus-
eptibility of this group of women to the complications of this
nfection. In this study, the possibility of response bias could
ot be ruled out. There is always a general tendency to give
ocially acceptable answers.
Performing routinely cervical cytological exam is
ecommended25,35 and in case of any degree of abnor-
ality in this evaluation women should be referred to
olposcopy assessment.36–38 HIV-infected women with cer-
ical invasive carcinoma normally present faster evolution
nd greater chance for disease recurrence.13 Cervical cancer
ncidence in HIV-infected women is not altered by use of
RV therapy.27,38 Therapeutic management is the same as for
ninfected women, irrespective of HIV serology,35 but with
oorer prognosis in women with AIDS.26,35
Cancer prevention programs exist and have been shown to
e successful at avoiding disease progression among women
nfected by HIV. Although this is encouraging, much work
till remains in order to identify additional innovative inter-
entions that address social, cultural, and environmental
nﬂuences of HPV infection and cervical cancer. There is also
 need to ﬁnd better ways of disseminating evidence-based
pproaches to HIV prevention, so that effective interventions
re more  widely used.35
In conclusion, it was demonstrated high prevalence of
igh-risk HPV infection in women living with HIV in Manaus,
eing signiﬁcantly associated with age less than 30 years old,
resence of high-grade SIL and CD4 counts <200 cells/mm3. In
ities of the Brazilian Amazon, access to sexual and reproduc-
ive care, contribute effectively to prevent lesions and cervical
ancer in this population.
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